September 11, 2020 | By Jeremy Loffredo | Children’s Health Defense |
“On Tuesday, AstraZeneca announced a pause on its experimental COVID-19 vaccine trial after a woman in the UK developed a “suspected serious reaction.” The company is also conducting trials in the U.S., South Africa and Brazil, with enrollment in all these countries on hold for now.
AstraZeneca is partnering with researchers at Oxford University to develop this vaccine, and is testing it on children as young as 5 years old. The World Health Organization’s Chief Scientist Soumya Swaminathan called the project a COVID-19 vaccine race “frontrunner” earlier this year.
The company asserts that a panel of independent experts will review the adverse reaction and decide whether or not AstraZeneca should lift the pause.
TM is a neurological disorder characterized by inflammation of the spinal cord, a major element of the central nervous system. It often results in weakness of the limbs, problems emptying the bladder and paralysis. Patients can become severely disabled and there is currently no effective cure.
Concerns over associations between TM and vaccines are well known. A review of published case studies in 2009 documented 37 cases of transverse myelitis associated with vaccines, including Hepatitis B, measles-mumps-rubella, diphtheria, pertussis, tetanus and others in infants, children and adults. The researchers in Israel noted “the associations of different vaccines with a single autoimmune phenomenon allude to the idea that a common denominator of these vaccines, such as an adjuvant, might trigger this syndrome.” Even the New York Times piece on the recent AstraZeneca trial pause notes past “speculation” that vaccines might be able to trigger TM.”